In a move that we hope will lead to faster development of therapies targeting Sarm1 in neurodegenerative diseases, Eli Lilly bought Disarm Therapeutics, the company cofounded by Aaron and Jeff. The Source has a nice write-up covering the Disarm’s founding and acquisition.